MORRISTOWN, N.J. (PRWEB) October 01, 2013
Capsugel announced today that it has completed its acquisition of Bend Research Inc., a recognized industry leader in bioavailability enhancement. Bend Research is now part of Capsugel's Dosage Form Solutions (DFS) business. DFS integrates Capsugel’s proprietary technology platforms, formulation R&D centers and finished dosage manufacturing sites to deliver innovative solutions to customers.
The acquisition announced earlier this month provides Capsugel DFS with best-in-class capability to help customers accelerate and improve development of pharmaceutical and nutritional products, especially in the areas of bioavailability enhancement and modified release. Bend Research brings expertise in novel formulations, including spray-dried dispersions and hot-melt extrusion, as well as technologies in the areas of controlled-release, inhalation and bio-therapeutics. These capabilities complement Capsugel DFS’ premier capabilities in lipid and liquid formulations, modified and targeted release delivery and specialized manufacturing solutions.
Capsugel is a global leader in providing innovative, high-quality dosage forms and solutions for the health care industry. With more than 100 years of experience, we provide a comprehensive array of advanced solutions to pharmaceutical and nutritional customers from formulation through clinical and commercial supply. From hard gelatin, liquid-filled and vegetarian capsules, to product development and manufacturing services, we help our customers improve their product profiles and accelerate development, and commercialization timelines. Capsugel is headquartered in Morristown, N.J., employs 2,900 people, has 12 manufacturing and R&D facilities across three continents, and serves more than 4,000 customers in over 100 countries. For additional information, visit http://www.capsugel.com.
ABOUT BEND RESEARCH
For more than 35 years, Bend Research has worked with clients to create value by advancing new medicines that improve human health and to solve their most difficult scientific and technical problems. This success is based on the company’s ability to develop, advance, and commercialize pharmaceutical technologies, which grow from a solid base of scientific and engineering fundamental understanding. Bend Research provides several capabilities, including formulation and dosage-form support, assists in process development and optimization, manufactures clinical trial quantities of drug candidates in its cGMP facilities, and advances promising drug candidates from conception through commercialization. The company is a leader in novel formulations, including spray-dried dispersions and hot-melt extrusion formulations, as well as controlled-release, inhalation, and biotherapeutics technologies. With 250 employees, Bend Research is based in Bend, Ore. For more information, visit http://www.bendresearch.com.
# # #
For media inquiries, contact Christina Chnaider at 610-680-6214 or christina(dot)chnaider(at)capsugel(dot)com